Grace Therapeutics (GRCE) News
NASDAQ: GRCEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
1.71-0.01 (-0.58%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GRCE news summary
We found 4 recent headlines mentioning Grace Therapeutics (GRCE): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, GRCE is down 0.58% at $1.71. The most recent story, "Grace Therapeutics Q2 Loss Widens Without Prior-Year Warrant Gain; Advances GTx-104 Plans", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Grace Therapeutics headlines
- Grace Therapeutics Q2 Loss Widens Without Prior-Year Warrant Gain; Advances GTx-104 Plans(RTTNews) - Grace Therapeutics, Inc. (GRCE) reported Thursday a wider fiscal second-quarter loss, mainly reflecting the absence of a prior-year warrant valuation gain.NasdaqGRCE, LEN.B
- Grace Therapeutics, Inc. Reports Financial Results for the Three Months Ended September 30, 2026 and Provides GTx-104 UpdateGrace Therapeutics, Inc. reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, an increase of $1.2 million from the net loss of $0.9 million, or…Nasdaq
- Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business UpdatePRINCETON, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable…GlobeNewswire
- Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026PRINCETON, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage,…GlobeNewswire